BerGenBio ASA (OTCPK:BRRGF)
$ 2.5 0 (0%) Market Cap: 27.51 Mil Enterprise Value: 17.20 Mil PE Ratio: 0 PB Ratio: 1.73 GF Score: 59/100

Bergenbio ASA to Discuss Top Line Data From Phase II Trial Assessing Bemcentinib in Hospitalised COVID-19 Patients Call Transcript

May 18, 2021 / 08:00AM GMT
Release Date Price: $352
Operator

Ladies and gentlemen, welcome to the BerGenBio conference Call. I'll now hand it over to the speakers. Please begin.

Richard Godfrey
BerGenBio ASA - CEO

Thank you very much, and good morning. This is Richard Godfrey, CEO of BerGenBio. Welcome to presentation of top line data from our Phase II trial assessing bemcentinib in hospitalized COVID-19 patients.

This morning, I'm joined by Dr. Akil Jackson, Medical Director from BerGenBio; and Professor Stener Kvinnsland, who's Director of BerGenBio Corporation and the former Chair of the Norwegian Korona Commission. As many of you will know, Stener Kvinnsland is (technical difficulty) in that capacity as Chairman of the Norwegian Korona Commission, and his insights are very salient and up to date.

Next slide, please. I should draw your attention to any forward-looking statements that may be made in this presentation and also the safe harbor comments made on this slide here.

Next slide, please. By way of executive summary, before I hand over to Akil Jackson for the presentation, I'd just

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot